1Zhu X,Bouzekri N,Southam L, et al. Linkage and association analysis of angiotensin 1 converting enzyme gene polymorphisms with ACE concentration and blood pressure [J].American Journal of Human Genetics, 2001,6(8): 1139.
2Ohnish Y, Tanaka T, Yamada R, et al. Identification of 187 single nucleotide polymorphisms (SNPs) among 41 candidate genes for ischemic heart disease in the Japanese population [J ]. Human Genetics, 2000, 10(6): 288.
3Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation[J] .Nucleic acids Research,2001, 2(9): 308.
4Muller PY, Miserez AR. Identifiction of mutations in the gene encoding sterol regulatory element binding protein (SREBP-2) in hypercholesterolaemic subjects[J], .Journal of Medical Genetics, 2002, 3(9) :271.
5Miserez AR, Muller PY, Barella L, et al. Sterol - regulatory element - binding protein(SREBP - 2) contributes to polygenic hypercholestorelemia[J ] . Atheroselerosis, 2002, 16(4):15.
6Brookes AJ, Lehvaslaiho H, Siegfried M, et al .HGBASE: a database of SNPs and other variations in and around human genes[J ]. Nucleic acids Research, 2000, 2(8): 356.
7Lifton RP. Molecular genetics of human blood pressure variation[J ]. Science, 1996, 27(2) :676.
8Richard P, David S. Molecular mechanisms of human hypertension[J ]. Cell, 2001, 10(4): 545.
9Rieder MJ, Taylor SL, Clark AG, et al. Sequence variation in the human angiotensin converting enzyme[J ] . Nature Genetics, 1999, 2(2) :59.
10Halushka MK, Fan JB, Bentley K, et al. Patterns of singlenucleotide polymorphisms in candidate genes for bloodpressure homeostasis [ J ]. Nature Genetics, 1999, 2(2): 239.
同被引文献8
1Yamada M. Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients [J]. Atheroscler Thromb, 1997, 4(1): 40-44.
2Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis[J]. Science, 1986, 232(4746): 34-47.
3Freedman DS, Otvos JD, Jeyarajah E J, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease [J]. Arterioscler Thromb Vase Biol, 1998, 18(7): 1046-1053.
4Shastry BS. Pharmacogenetics and the concept of individualized medicine[J]. The Pharmacogenomics J, 2006, 6(2); 16-21.
5Barter P, Kastelein J, Nunn A, et al. CN-FFEB: high density lipoproteins (HDLs) and atherosclerosis; the unanswered questions[J]. Atherosclerosis, 2003, 168(2): 195-211.
6Brewer Jr H B, Santamarina-Fojo S. Clinical significance of high density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter[J]. Am J Cardiol, 2003, 92(4B): 10K-6K.
7Sadaf A, Siddiqui S, Lestringant GG, et al. Apolipoprotein AI promoter variant in blood pressure determination[J]. Clin Genet, 2002, 61(4): 314-316.
8Wang XL, Badenhop K, Humphrey K, et al. C to T and G to A transitions are responsible for loss of a MspI restriction site in the 5%- region of the human apolipoprotein AI gene[J]. Hum Genet, 1995, 95(4): 473-475.
